bio techne r d system Search Results


ctla 4  (Bio-Techne corporation)
93
Bio-Techne corporation ctla 4
Ctla 4, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm37075987-56-12-14?v=Bio-Techne+corporation
Average 93 stars, based on 1 article reviews
ctla 4 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
tnfr1 antagonist  (Tocris)
92
Tocris tnfr1 antagonist
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Tnfr1 Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc10880026-57-3-13?v=Tocris
Average 92 stars, based on 1 article reviews
tnfr1 antagonist - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
tnf α levels assessment by elisa  (R&D Systems)
95
R&D Systems tnf α levels assessment by elisa
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Tnf α Levels Assessment By Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc08018350-366-8-23?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
tnf α levels assessment by elisa - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
recombinant il 7  (R&D Systems)
95
R&D Systems recombinant il 7
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Recombinant Il 7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc11452968-73-20-22?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
recombinant il 7 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
matrigel growth factor reduced, phenol red-free, ldev-free  (Corning Life Sciences)
90
Corning Life Sciences matrigel growth factor reduced, phenol red-free, ldev-free
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Matrigel Growth Factor Reduced, Phenol Red Free, Ldev Free, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc11579301-337-8-15?v=Corning+Life+Sciences
Average 90 stars, based on 1 article reviews
matrigel growth factor reduced, phenol red-free, ldev-free - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
anti sdf 1a antibody  (Bio-Techne corporation)
99
Bio-Techne corporation anti sdf 1a antibody
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Anti Sdf 1a Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm28550195-74-9-12?v=Bio-Techne+corporation
Average 99 stars, based on 1 article reviews
anti sdf 1a antibody - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
pd 1  (Bio-Techne corporation)
93
Bio-Techne corporation pd 1
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Pd 1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm37075987-56-19-21?v=Bio-Techne+corporation
Average 93 stars, based on 1 article reviews
pd 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
human il 6  (Bio-Techne corporation)
99
Bio-Techne corporation human il 6
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Human Il 6, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm35453313-99-29-32?v=Bio-Techne+corporation
Average 99 stars, based on 1 article reviews
human il 6 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
bio techne r d system  (R&D Systems)
96
R&D Systems bio techne r d system
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Bio Techne R D System, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm40000515-64-17-18?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
bio techne r d system - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
recombinant mouse ptn  (R&D Systems)
94
R&D Systems recombinant mouse ptn
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Recombinant Mouse Ptn, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc11507919-198-9-17?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant mouse ptn - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
antibody against survivin  (Bio-Techne corporation)
95
Bio-Techne corporation antibody against survivin
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Antibody Against Survivin, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pm34033881-147-7-13?v=Bio-Techne+corporation
Average 95 stars, based on 1 article reviews
antibody against survivin - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
bio techne r d systems  (R&D Systems)
97
R&D Systems bio techne r d systems
Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
Bio Techne R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bio+techne+r+d+system/pmc11203750-83-5-6?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
bio techne r d systems - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

Image Search Results


Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Injection, Comparison

Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Control, Comparison